Wellgistics Management Converts $2 Million in Deferred Compensation into Equity at $0.20 per Share

Rhea-AI Summary

Wellgistics (NASDAQ:WGRX) announced that its President and Interim CEO Prashant Patel and one board participant converted approximately $2.0 million of accrued compensation into common stock at $0.20 per share, resulting in issuance of ~10,000,000 shares.

The company also issued 10,000,000 warrants exercisable at $0.01 for five years, and the converted shares are subject to a 6-month lock-up. The board approved the conversion to align management incentives with long-term shareholder value.

Positive

• $2.0M accrued compensation converted into equity
• 10,000,000 warrants issued with immediate exercisability
• Converted shares subject to a 6-month lock-up

Negative

• Issuance of 10,000,000 shares may dilute existing shareholders
• Warrants exercisable at $0.01 could cause additional dilution if exercised

Market Reaction – WGRX

-15.09% $0.11

15m delay 8 alerts

-15.09% Since News

$0.11 Last Price

$0.11 $0.13 Day Range

-$2M Valuation Impact

$10M Market Cap

0.5x Rel. Volume

Following this news, WGRX has declined 15.09%, reflecting a significant negative market reaction. Our momentum scanner has triggered 8 alerts so far, indicating moderate trading interest and price volatility. The stock is currently trading at $0.11. This price movement has removed approximately $2M from the company's valuation.

Data tracked by StockTitan Argus (15 min delayed). Upgrade to Silver for real-time data.

Key Figures

Deferred compensation converted: $2.0 million Conversion price: $0.20 per share Common shares issued: 10,000,000 shares +5 more

8 metrics

Deferred compensation converted $2.0 million Aggregate accrued compensation converted to equity

Conversion price $0.20 per share Price for issuing common stock in conversion

Common shares issued 10,000,000 shares Shares of common stock issued for conversion

Warrants issued 10,000,000 warrants Additional consideration tied to compensation conversion

Warrant exercise price $0.01 per share Exercise price for newly issued warrants

Warrant term 5 years Duration from warrant issuance

Lock-up period 6 months Restriction period on transfers of new common shares

Pre-news price change -14.22% 24h move before announcement

Market Reality Check

Price: $0.1339 Vol: Volume 2,838,088 vs 20-da...

low vol

$0.1339 Last Close

Volume Volume 2,838,088 vs 20-day average 5,031,677 (relative volume 0.56). low

Technical Trading below 200-day MA of 0.74 with pre-news price at 0.1339, near 52-week low 0.1292 and far below 52-week high 7.04.

Peers on Argus

Pre-news, WGRX was down 14.22% while peers were mixed: PETS (-1.58%), HITI (-9.2...

1 Down

Pre-news, WGRX was down 14.22% while peers were mixed: PETS (-1.58%), HITI (-9.26%), HKPD (+0.30%), SCNX (+7.18% but flagged in momentum as down intraday), SSY (+9.31%). Only one peer appeared in the momentum scanner, suggesting stock-specific dynamics rather than a coordinated sector move.

Historical Context

5 past events · Latest: Mar 13 (Positive)

Pattern 5 events

Date	Event	Sentiment	Move	Catalyst
Mar 13	Strategy letter	Positive	-1.8%	CEO letter outlining patient-centric strategy and online pharmacy expansion.
Mar 11	Platform expansion	Positive	+5.4%	Added insurance eligibility and benefits verification capabilities to EinsteinRx.
Mar 09	Product launch	Positive	+5.8%	Launch of Forzet medical food targeting GLP-1 therapy–related muscle loss.
Mar 05	Blockchain rollout	Positive	-9.2%	Selection of five blockchain platforms for PharmacyChain drug tracking.
Feb 23	Partnership expansion	Positive	+9.8%	Expanded Datavault AI partnership for HaaS blockchain-enabled smart contracts.

Pattern Detected

Recent strategic and partnership announcements often carried positive tone but produced mixed price reactions, with both rallies and selloffs following upbeat news.

Recent Company History

Over the past few months, Wellgistics has reported several strategic initiatives, including GLP-1–related product launches, blockchain-based PharmacyChain™ development, and expanded AI-enabled services. Events on Feb 23, Mar 5, Mar 9, Mar 11, and Mar 13 highlighted partnerships, new products, and platform enhancements. Market reactions to these generally positive updates alternated between gains and pullbacks, indicating investor uncertainty around execution and capital structure. Today’s management compensation-to-equity conversion fits into this broader transformation narrative.

Market Pulse Summary

The stock is dropping -15.1% following this news. A negative reaction despite management’s conversio...

Analysis

The stock is dropping -15.1% following this news. A negative reaction despite management’s conversion of $2.0 million in deferred compensation into equity at $0.20 per share would fit a pattern where upbeat strategic news sometimes coincided with selloffs. The issuance of 10,000,000 new shares plus 10,000,000 warrants at a $0.01 exercise price increases potential dilution, which could have outweighed the insider alignment and liability reduction in investor perceptions.

Key Terms

deferred compensation, warrants, exercise price, anti-dilution adjustments, +1 more

5 terms

deferred compensation financial

"converts $2.0 million of accrued compensation into shares of the Company's common stock"

Deferred compensation is pay that employees or executives have earned now but will receive at a later date, such as delayed bonuses, retirement benefits, or stock grants. It matters to investors because it creates future obligations and shapes incentives—like a promise to pay later that can affect a company’s reported profits, cash needs and potential stock dilution—so it helps signal how a business manages costs and retains key people.

warrants financial

"issued an aggregate of 10,000,000 warrants to purchase shares of common stock"

Warrants are special documents that give you the right to buy a company's stock at a set price before a certain date. They are often used as a way for companies to attract investors or raise money, and their value can increase if the company's stock price goes up.

exercise price financial

"warrants to purchase shares of common stock at an exercise price of $0.01 per share"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

anti-dilution adjustments financial

"The Warrants are exercisable immediately, have a term of 5 years ... and are subject to customary anti-dilution adjustments."

Anti-dilution adjustments are changes made to the ownership stakes or value of an investment to protect investors from having their shares become less valuable if the company issues new shares at a lower price. Imagine buying a piece of a pie, and then the pie is cut into more slices without increasing in size—these adjustments help ensure your slice still retains its worth. They matter to investors because they help preserve the value of their investment when the company’s share price drops.

lock-up agreement financial

"subject to a lock-up agreement restricting transfers for a period of 6 months"

A lock-up agreement is a contract that prevents company insiders and early investors from selling their shares for a fixed period after a stock sale, often after an initial public offering. It matters to investors because it temporarily limits the number of shares that can hit the market, which can keep the share price steadier; when the lock-up ends, a sudden increase in available shares can create extra volatility, revealing insiders’ confidence or lack thereof.

AI-generated analysis. Not financial advice.

TAMPA, FL / ACCESS Newswire / March 19, 2026 / Wellgistics Health, Inc. (NASDAQ:WGRX) ("Wellgistics"), a health information technology leader, integrating proprietary pharmacy dispensing optimization artificial intelligence (AI) platform EinsteinRx^™ into its patented blockchain-enabled smart contracts platform PharmacyChain^™, today announced that its President and Interim Chief Executive Officer, Prashant Patel, together with an additional participant from the Company's Board of Directors, entered into agreements with the Company to convert an aggregate of approximately $2.0 million of accrued compensation into shares of the Company's common stock at a conversion price of $0.20 per share, representing a premium to the Company's recent trading price. In connection with the conversion, the Company will issue approximately 10,000,000 shares of common stock.

In addition, the Company issued an aggregate of 10,000,000 warrants to purchase shares of common stock at an exercise price of $0.01 per share (the "Warrants"), which were issued as additional consideration in connection with the conversion. The Warrants are exercisable immediately, have a term of 5 years from issuance, and are subject to customary anti-dilution adjustments.

This conversion, which was approved by the disinterested directors of the Board, reflects Mr. Patel's confidence in the Company's strategic direction and his commitment to creating long-term shareholder value. Further reinforcing Mr. Patel's belief in the Company's long-term success, the newly issued shares of the Company's common stock are subject to a lock-up agreement restricting transfers for a period of 6 months, subject to customary exceptions.

The structure of the transaction, including the issuance of Warrants, was designed to align management and director incentives with long-term shareholder value creation.

"I believe Wellgistics has the potential to build upon its vision and bring long lasting value to all healthcare stakeholders," said Mr. Patel. "This conversion reinforces my unwavering belief in our team, our mission, and the transformative impact we will have on the future of healthcare."

About Wellgistics Health, Inc.

Wellgistics Health (NASDAQ:WGRX) is a health information technology leader, integrating proprietary pharmacy dispensing optimization artificial intelligence platform EinsteinRx^™ into its patented blockchain-enabled smart contracts platform PharmacyChain^™ to optimize the prescription drug dispensing journey. Its integrated platform connects 6,500+ pharmacies (the "Wellgistics Pharmacy Network") and 200+ manufacturers, offering wholesale distribution, digital prescription routing, direct-to-patient delivery, and AI-powered hub services such as eligibility, adherence, onboarding, prior authorization, and cash-pay fulfillment as needed to optimize patient access. Wellgistics provides end-to-end solutions designed to restore access, transparency, and trust in the U.S. prescription drug market for independent pharmacies.

For more information, visit www.wellgisticshealth.com.

Forward-Looking Statements

This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements generally relate to future events or the Company's future financial or operating performance and may include, without limitation, statements regarding the expected benefits of the debt conversion transaction, including its anticipated impact on the Company's balance sheet, liquidity, capitalization, and alignment of management and director interests with those of stockholders, as well as the Company's strategic plans, growth initiatives, and long-term value creation.

In some cases, forward-looking statements can be identified by terminology such as "may," "will," "should," "expects," "plans," "anticipates," "believes," "intends," "estimates," "projects," "potential," "continue," or the negative of these terms or other comparable terminology. These statements are based on current expectations, estimates, and assumptions and involve risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such forward-looking statements.

These risks and uncertainties include, without limitation, risks related to the Company's ability to realize the anticipated benefits of the debt conversion transaction; the potential dilutive impact of the issuance of common stock and warrants, including upon exercise of the warrants; the Company's ability to maintain compliance with Nasdaq listing standards; market conditions and volatility in the Company's stock price; the Company's ability to execute its business strategy and growth initiatives; and other risks and uncertainties described from time to time in the Company's filings with the U.S. Securities and Exchange Commission.

Forward-looking statements speak only as of the date of this press release, and the Company undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise, except as required by law.

Wellgistics Media & Investor Contact

Media:
media@wellgisticshealth.com

Investor Relations:
IR@wellgisticshealth.com

SOURCE: Wellgistics Health, Inc.

View the original press release on ACCESS Newswire

FAQ

What did Wellgistics (WGRX) announce on March 19, 2026 about deferred compensation conversion?

They converted approximately $2.0 million of accrued compensation into common stock at $0.20 per share. According to the company, this resulted in issuance of roughly 10,000,000 shares plus 10,000,000 warrants as additional consideration.

How many warrants did Wellgistics (WGRX) issue and what are their terms?

Wellgistics issued an aggregate of 10,000,000 warrants, exercisable immediately at $0.01 per share. According to the company, the warrants have a 5-year term and include customary anti-dilution adjustments.

Will the newly issued Wellgistics (WGRX) shares be restricted after conversion?

Yes, the newly issued shares are subject to a 6-month lock-up with customary exceptions. According to the company, this restriction was placed to demonstrate management's commitment to long-term shareholder value.

Who approved the deferred compensation conversion at Wellgistics (WGRX)?

The conversion was approved by the company's disinterested directors of the board. According to the company, disinterested directors reviewed and approved the transaction to address conflicts of interest.

What immediate shareholder impact should investors expect from Wellgistics (WGRX) conversion?

Investors should expect potential dilution from the issuance of ~10,000,000 shares and exercisable warrants. According to the company, the structure aims to align management incentives with long-term value despite near-term dilution risk.